BCK Capital Management LP bought a new position in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 22,000 shares of the biotechnology company’s stock, valued at approximately $933,000.
Other hedge funds also recently made changes to their positions in the company. GAM Holding AG purchased a new position in shares of Cerevel Therapeutics in the 4th quarter worth about $212,000. FNY Investment Advisers LLC purchased a new position in shares of Cerevel Therapeutics in the 4th quarter worth about $339,000. PNC Financial Services Group Inc. boosted its holdings in shares of Cerevel Therapeutics by 68.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 9,506 shares of the biotechnology company’s stock worth $208,000 after buying an additional 3,866 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Cerevel Therapeutics by 8.8% in the 4th quarter. Amalgamated Bank now owns 10,027 shares of the biotechnology company’s stock worth $425,000 after buying an additional 809 shares during the last quarter. Finally, E Fund Management Co. Ltd. lifted its holdings in Cerevel Therapeutics by 7.6% during the third quarter. E Fund Management Co. Ltd. now owns 10,223 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 722 shares during the last quarter. 87.73% of the stock is currently owned by institutional investors.
Insider Transactions at Cerevel Therapeutics
In related news, insider John Renger sold 2,161 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $41.54, for a total value of $89,767.94. Following the transaction, the insider now directly owns 6,370 shares in the company, valued at $264,609.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider John Renger sold 2,161 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $41.54, for a total value of $89,767.94. Following the transaction, the insider now directly owns 6,370 shares in the company, valued at $264,609.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director N Anthony Coles sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $41.16, for a total transaction of $2,058,000.00. Following the completion of the transaction, the director now owns 15,638 shares in the company, valued at $643,660.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 104,667 shares of company stock valued at $4,302,367. 5.10% of the stock is currently owned by corporate insiders.
Cerevel Therapeutics Price Performance
Analyst Ratings Changes
Separately, Mizuho upped their price objective on shares of Cerevel Therapeutics from $25.00 to $45.00 and gave the company a “neutral” rating in a report on Friday, February 16th. Eight equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, Cerevel Therapeutics has a consensus rating of “Hold” and an average target price of $42.67.
View Our Latest Report on CERE
About Cerevel Therapeutics
Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.
Featured Articles
- Five stocks we like better than Cerevel Therapeutics
- Find and Profitably Trade Stocks at 52-Week Lows
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- How Can Investors Benefit From After-Hours Trading
- 3 Value Stocks You Can Buy Before They Become Big
- Best Aerospace Stocks Investing
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.